For U.S. Residents Only
A A A

Change font size  A A A Email Print Prescribing Information Site Map

Close

Lantus® is a once-daily, long-acting insulin that provides 24-hour basal
coverage with no pronounced peak.1

How Lantus® Works Lantus® Efficacy Lantus® Safety Lantus®
SoloSTAR® Pen
View video
  1. Lantus® Prescribing Information. October 2013.
Close

Dosing guidelines and titration for Lantus®

Dosing Titration
Interactive dosing calculator Titration options
Close

Education is an important part of prescribing insulin therapy to help manage
patients' concerns about insulin use.

Therapy Considerations Initiating Treatment Improving Self-Management
Stepwise Approach
Close

Provide educational support for your patients with type 2 diabetes.
Help them understand, know what to expect, and become active participants in their own care.

Day by Day Guide Explaining Diabetes to Patients Getting Patients Started Improving Patient
Self-Care Skills
Useful guides to reinforce your conversations with patients
Close

There are a variety of ways Sanofi can help your patients access their insulin therapy.

Formulary Tool Patient Assistance Savings Offer
Save on Lantus® SoloSTAR®

* Certain eligibility restrictions apply

Close

Tools, links, and educational materials to help you support patients move
toward their glycemic goals.

Professional Resources Patient Resources
Educational materials

Features of the Lantus® SoloSTAR® Pen

The Lantus® SoloSTAR® pen is designed for ease of use and has optimized dose and injection features.

Ultra thin needles

Large-print dosing window

Push-button injection

The Lantus® SoloSTAR® pen is:

  • Prefilled with the #1 prescribed insulina
  • Easy to teach, with only 6 straightforward steps1,2
  • Easy to use—dial lets patients select the appropriate Lantus® dose from 1 to 80 units, 1 unit at a time1,2
  • Easy to inject—dose cannot be dialed past the number of units left in the pen2,3
    • It is important to keep the injection button pressed all the way in and to slowly count to 10 before withdrawing needle from skin. After a full injection, the number in the dose window will return to zero. These steps help ensure that a full dose has been delivered
    • Insulin dose dialed is the dose delivered4
    • Dose dial returns to zero once dose has been delivered
  • Portable5—once opened, the Lantus® SoloSTAR® pen can be used for up to 28 days and should not be refrigerated. Instruct patients to keep the opened Lantus® SoloSTAR® pen at room temperature (below 86°F). Lantus® SoloSTAR® pens must be discarded 28 days after being opened6

More Lantus® units per prescription with Lantus® SoloSTAR® b,c

  • 50% more insulin units for the same copay as a single vial and syringe on most managed care plans
  • 1 box of 5 SoloSTAR® pensd = 1500 units vs 1 viale = 1000 units

Units per prescription

Lantus® Savings Card Program

Qualifying Lantus® SoloSTAR® pen users pay no more than $25* per prescription with the Lantus® Savings Card for the program duration.

Lantus® Savings

Let patients know they can apply at LantusSavings.com

*Certain eligibility restrictions apply. See savings card for details.

Indications and Usage for Lantus® (insulin glargine [rDNA origin] injection)

Lantus® is a long-acting insulin analog indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. Lantus® should be administered once a day at the same time every day.

Important Limitations of Use: Lantus® is not recommended for the treatment of diabetic ketoacidosis. Use intravenous short-acting insulin instead.

Important Safety Information for Lantus® (insulin glargine [rDNA origin] injection)

Contraindications

Lantus® is contraindicated in patients hypersensitive to insulin glargine or one of its excipients.

Warnings and Precautions

Monitor blood glucose in all patients treated with insulin. Modify insulin regimen cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type, or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment.

Do not dilute or mix Lantus® with any other insulin or solution. If mixed or diluted, the solution may become cloudy, and the onset of action/time to peak effect may be altered in an unpredictable manner. Do not administer Lantus® via an insulin pump or intravenously because severe hypoglycemia can occur. Insulin devices and needles must not be shared between patients.

Hypoglycemia is the most common adverse reaction of insulin therapy, including Lantus®, and may be life-threatening.

Severe life-threatening, generalized allergy, including anaphylaxis, can occur. Discontinue Lantus®, monitor and treat if indicated.

A reduction in the Lantus® dose may be required in patients with renal or hepatic impairment.

Fluid retention, which may lead to or exacerbate heart failure, can occur with concomitant use of thiazolidinediones (TZDs) with insulin. These patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of TZD must be considered.

Drug Interactions

Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose. The signs of hypoglycemia may be reduced in patients taking anti-adrenergic drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine).

Adverse Reactions

Adverse reactions commonly associated with Lantus® include hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, edema and weight gain.

Important Safety Information for Lantus® SoloSTAR®

Lantus® SoloSTAR® is a disposable prefilled insulin pen. To help ensure an accurate dose each time, patients should follow all steps in the Instruction Leaflet accompanying the pen; otherwise they may not get the correct amount of insulin, which may affect their blood glucose.

Please click here for Full Prescribing Information for Lantus®.

Click here to learn more about Sanofi's commitment to fighting counterfeit drugs.

aBased on TRx data from IMS Health, NPA™ monthly database, time period from May 2003 to November 2011.
bWhen prescribed as one box of 5 x 3 ml pens.
cWhen vial and SoloSTAR® have equal tier coverage.
dA prescription for 1 box of 5 pens.
eA prescription for 1 vial.
fThe SoloSTAR® pen is recommended for use with Becton, Dickinson and Company pen needles.

References:

  1. Carter J, Beilin J, Morton A, De Luise M. J Diabetes Sci Technol. 2009 ;3(6) ;1425-1438
  2. Data on file, Sanofi U.S. LLC.
  3. Clarke A, Spollett G. Expert Opin Drug Deliv. 2007;4(2):165-174.
  4. Krzywon M, Abdel-Tawab M, van der Burg T, Fuhr U, Schubert-Zsilavecz M. Curr Med Res Opin. 2010;26(4):901-905.
  5. Haak T, Edelman S. Walter C, et al. Clin Ther. 2007;29(4):650-660.
  6. Lantus® Prescribing Information. October 2013.

Indications and Usage for Lantus® (insulin glargine [rDNA origin] injection)

Lantus® is a long-acting insulin analog indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. Lantus® should be administered once a day at the same time every day.

Important Limitations of Use: Lantus® is not recommended for the treatment of diabetic ketoacidosis. Use intravenous short-acting insulin instead.

Important Safety Information for Lantus® (insulin glargine [rDNA origin] injection)

Contraindications

Lantus® is contraindicated in patients hypersensitive to insulin glargine or one of its excipients.

Warnings and Precautions

Monitor blood glucose in all patients treated with insulin. Modify insulin regimen cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type, or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment.

Important Safety Information for Lantus® SoloSTAR®

Lantus® SoloSTAR® is a disposable prefilled insulin pen. To help ensure an accurate dose each time, patients should follow all steps in the Instruction Leaflet accompanying the pen; otherwise they may not get the correct amount of insulin, which may affect their blood glucose.

Click here for additional Important Safety Information.

  • Indications and Usage for Lantus®

    (insulin glargine [rDNA origin] injection)

    Lantus® is a long-acting insulin analog indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. Lantus® should be administered once a day at the same time every day.

    Important Limitations of Use: Lantus® is not recommended for the treatment of diabetic ketoacidosis. Use intravenous short-acting insulin instead.

    Important Safety Information for Lantus®

    (insulin glargine [rDNA origin] injection)

    Contraindications
    Lantus® is contraindicated in patients hypersensitive to insulin glargine or one of its excipients.

    Warnings and Precautions
    Monitor blood glucose in all patients treated with insulin. Modify insulin regimen cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type, or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment.

    Do not dilute or mix Lantus® with any other insulin or solution. If mixed or diluted, the solution may become cloudy, and the onset of action/time to peak effect may be altered in an unpredictable manner. Do not administer Lantus® via an insulin pump or intravenously because severe hypoglycemia can occur. Insulin devices and needles must not be shared between patients.

    Hypoglycemia is the most common adverse reaction of insulin therapy, including Lantus®, and may be life-threatening.

    Severe life-threatening, generalized allergy, including anaphylaxis, can occur. Discontinue Lantus®, monitor and treat if indicated.

    A reduction in the Lantus® dose may be required in patients with renal or hepatic impairment.

    Fluid retention, which may lead to or exacerbate heart failure, can occur with concomitant use of thiazolidinediones (TZDs) with insulin. These patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of TZD must be considered.

    Drug Interactions
    Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose. The signs of hypoglycemia may be reduced in patients taking anti-adrenergic drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine).

    Adverse Reactions
    Adverse reactions commonly associated with Lantus® include hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, edema and weight gain.

    Important Safety Information for Lantus® SoloSTAR®

    Lantus® SoloSTAR® is a disposable prefilled insulin pen. To help ensure an accurate dose each time, patients should follow all steps in the Instruction Leaflet accompanying the pen; otherwise they may not get the correct amount of insulin, which may affect their blood glucose.

    Click here for Full Prescribing Information for Lantus®.

    Click here for information on drug anti-counterfeiting.

Bookmark this page
or add it to your home screen
for quick access